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Background/aim: This study aimed to evaluate the role of adjuvant therapy for stage I uterine leiomyosarcoma (LMS).
Materials and methods: Clinicopathological data of cases of stage I uterine LMS from 1998 to 2015 were retrieved from the computerized
database of Hacettepe University Hospital. The Kaplan–Meier method was used to estimate survival and progression-free survival, and
survival differences were analyzed by log-rank test. Cox regression analysis was performed to account for the potential inﬂuence of
confounding factors.
Results: We evaluated the outcomes of 35 patients with histologically proven stage I LMS. The median age at diagnosis was 50 years.
All patients underwent surgical treatment and 20 patients (57.1%) received adjuvant therapy. Twelve of these patients (34.3%) received
adjuvant chemotherapy, 3 (8.6%) received adjuvant pelvic irradiation, and 5 (14.2%) received adjuvant chemotherapy with pelvic
irradiation. The median follow-up duration was 34 months (range: 3–231 months). Twenty-three (65.7%) patients had a recurrence
during follow-up. Adjuvant therapy did not significantly improve median progression-free survival or median overall survival. Cox
regression analysis did not demonstrate any significant impact of the factors studied, including age, menopausal status, tumor size,
mitotic count, staging surgery, or adjuvant therapy.
Conclusion: Adjuvant therapy for surgically treated stage I uterine LMS did not improve oncologic outcomes.
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1. Introduction
Leiomyosarcoma (LMS) of the uterus is a rare tumor that
accounts for approximately 1% of all uterine malignant
neoplasms and arises from the smooth muscle cells of
the uterus. This malignancy is a highly aggressive tumor
compared with other uterine cancers and it is associated
with a significant risk of recurrence and death, even in
early stages (1,2).
The main treatment for LMS is surgical excision
including total abdominal hysterectomy with or without
bilateral salpingo-oophorectomy (2,3). However,
debulking of any tumor outside the uterus should be a goal
of the surgery since the most important prognostic factor
is residual disease following primary surgery (1,4).
LMS is staged by the 2009 International Federation of
Gynecology and Obstetrics (FIGO) staging system and
stage I LMS is defined as a tumor confined to the corpus
of the uterus (5). Although LMS is usually diagnosed at an
early stage, its prognosis is very poor. Most patients will
develop recurrence after primary treatment even if the
* Correspondence: gokhan.boyraz@gmail.com

disease is confined to the uterus. Five-year disease-specific
survival for patients with stage I and II disease is 51% and
25%, respectively. For all stages of patients with LMS of the
uterus, 5-year disease specific survival is only 32% (1,6).
The current recommendations for adjuvant treatment
in uterine LMS remain controversial. After surgery,
adjuvant treatment with pelvic radiotherapy and/or
chemotherapy may be considered (7,8). However, it is not
clear whether any adjuvant therapy options offer a survival
benefit. Furthermore, results are conflicting regarding
the adjuvant treatment especially for patients with stage
I uterine LMS. Therefore, the aim of this study was to
evaluate the role of adjuvant treatment in patients with
stage I LMS of the uterus.
2. Materials and methods
This retrospective study included patients with histologically
proven stage I uterine LMS. Clinicopathological and
outcome data of patients with FIGO stage I uterine LMS
from 1998 to 2015 were retrieved from the computerized
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database of Hacettepe University Hospital. The clinical and
pathological characteristics including age, menopausal
status, operative procedure, tumor size, mitotic count,
stage, adjuvant treatment, and survival were determined
and compared. All patients were staged according to the
2009 FIGO staging system. Uterine LMS was pathologically
diagnosed by the presence of coagulative tumor cell
necrosis, cytologic atypia, and 10 or more mitoses per 10
high-power fields.
Data recording and statistical analyses were performed
using SPSS 16.0 (SPSS Inc., Chicago, IL, USA). Basic
characteristics were compared by using the Mann–
Whitney U test or chi-square test as appropriate. Overall
survival (OS) was calculated from time of diagnosis until
death or time of last follow-up. Progression-free survival
(PFS) was calculated from time of diagnosis until the
diagnosis of disease recurrence. The Kaplan–Meier method
was used to estimate OS and PFS, and survival differences
were analyzed by log-rank test. Cox regression analysis
was performed to account for the potential inﬂuence
of confounding factors. Differences were considered
statistically significant at P < 0.05.
As this study represents a retrospective database
review, local ethics committee permission was not sought.

3. Results
Outcomes of 35 patients with histologically proven stage
I LMS were evaluated. The median age at diagnosis was
50 years (range: 22–66). Twenty (57.1%) patients were
postmenopausal and 15 (42.9%) were premenopausal.
Demographic, clinical, and pathological characteristics of
the study patients are presented in Table 1.
All patients underwent surgical treatment and 20
patients (57.1%) received postoperative adjuvant therapy
(Table 2). The surgical procedure consisted of total
abdominal hysterectomy (TAH) and bilateral salpingooophorectomy (BSO) in 14 (40%) patients, surgical
staging with lymphadenectomy and omentectomy in
addition to TAH and BSO in 9 (25.7%) patients, and TAH
alone in 2 (5.7%) patients. Ten patients were referred after
having TAH+BSO or TAH at other centers. Of these, 9
patients underwent lymphadenectomy and omentectomy,
while 1 patient underwent BSO, lymphadenectomy,
and omentectomy. Of patients who received adjuvant
treatment, 12 (34.3%) received chemotherapy (ifosfamide ±
adriamycin or docetaxel + gemcitabine), 3 (8.6%) received
pelvic irradiation, and 5 (14.2%) received chemotherapy
with pelvic irradiation. The median follow-up duration was
34 months (range: 3-231 months). Twenty-three (65.7%)
patients experience a recurrence during follow-up (Table
3). The median PFS and median OS were similar between

Table 1. Basic demographic and histopathological characteristics of patients.
Adjuvant therapy (n = 20)
Characteristic

No (n = 15)

Yes (n = 20)

P

Age at diagnosis, years

51.1 ± 14.5

47.6 ± 10.1

NS*

Maximal tumor size (cm)

8.5 ± 5.7

9.1 ± 3.4

NS*

Mitotic count (per 10 HPFs)

14.6 ± 5.9

20.7 ± 10.7

NS*

Median follow-up, months (range)

36 (3–113)

31 (6–231)

NS*

Stage

NS#

IA

3 (20.0%)

2 (10.0%)

IB

12 (80.0%)

18 (90.0%)

Menopausal status
Premenopausal

6 (40.0%)

9 (45.0%)

Postmenopausal

9 (60.0%)

11 (55.0%)

Data are given as mean ± SD or n (%).
HPF, High-power field; NS, nonsignificant.
*
Mann–Whitney U test, #chi-square test.
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Table 2. Primary surgical procedures and adjuvant treatments.
Number

Percent

TAH

2

5.7

TAH + BSO

14

40.0

TAH + BSO + LND + omentectomy

9

25.7

LND + omentectomy

9

25.7

1

2.9

No adjuvant therapy

15

42.9

Chemotherapy

12

34.3

Radiotherapy

3

8.5

Chemotherapy and radiotherapy

5

14.3

Type of surgery

*

BSO + LND + omentectomy

#

Adjuvant therapy

TAH, Total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; LND,
lymph node dissection.
*
Patients who were referred after having TAH + BSO at other centers.
#
Patients who were referred after having TAH at other centers.
Table 3. Recurrence rates and patterns according to adjuvant treatment status.
No adjuvant therapy
(n = 15)

Adjuvant therapy
(n = 20)

Recurrence

P
NS*

Yes

8 (53.3%)

15 (75.0%)

No

7 (46.7%)

5 (25.0%)

Sites of recurrence

NS*

Pelvis

4 (50.0%)

9 (60.0%)

Lung

3 (37.5%)

5 (33.3%)

Pelvis and lung

0

1 (6.7%)

Subcutaneous nodules

1 (12.5%)

0

Data are given as n (%).

patients who received adjuvant treatment compared with
those who did not receive adjuvant therapy (Figures 1
and 2). Cox regression analysis did not demonstrate any
significant impact of the factors studied on median PFS
and OS. These factors included age, menopausal status,
tumor size, mitotic count, staging surgery, and adjuvant
therapy.

4. Discussion
Patients with uterine LMS have a high risk of recurrence
and mortality, regardless of the stage of the disease.
Recurrence rates vary between 53% and 71% (9,10).
Abeler et al. found that patients with early stage (stage I)
uterine LMS had an overall 5-year survival of 51% (11).
However, in the literature, there is limited information
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Figure 1. Progression-free survival of patients with stage I uterine LMS.

Figure 2. Overall survival of patients with stage I uterine LMS.
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on the role of postoperative adjuvant treatment despite
these high recurrence and mortality rates. Chemotherapy
and/or pelvic radiotherapy may be considered following
the surgery for uterine LMS. While adjuvant pelvic
radiotherapy may be used to reduce the risk of local
recurrences, systemic recurrences and metastatic disease
may be prevented with chemotherapy. However, the
effectiveness of any form of adjuvant treatment on survival
has not been consistently shown (1,12).
In a Gynecologic Oncology Group (GOG) study, 156
patients with stage I (disease limited to corpus) or stage II
(disease limited to the corpus and cervix) uterine sarcomas
were evaluated in a randomized study. Patients receiving
adjuvant chemotherapy consisting of doxorubicin were
compared with those not receiving adjuvant therapy.
Pelvic irradiation was optional before randomization.
Although women who received doxorubicin had a lower
recurrence rate, this was not statistically significant. There
was no difference in PFS or OS (13). On the other hand,
Hensley et al. designed a prospective study and evaluated
23 patients with completely resected stage I–IV uterine
LMS. All patients were treated with adjuvant gemcitabine
and docetaxel. Of these 23 patients, 18 were at stage I or II.
Among these 18 patients, 2-year PFS was found to be 59%
and median PFS was 39 months. The authors concluded
that adjuvant treatment with gemcitabine plus docetaxel
for uterine LMS yielded higher PFS rates than historical
rates (14). Another important study for adjuvant treatment
with chemotherapy in patients with uterus-limited LMS
was published by Hensley et al. In this study, 47 patients
with uterus-limited LMS received 4 cycles of gemcitabine
plus docetaxel followed by doxorubicin. The median time
to recurrence was 27 months, the 2-year PFS rate was 78%,
and the 3-year PFS rate was 57% (15). Similarly, Piver et
al. showed a low recurrence rate in patients with stage I
LMS who were treated with adjuvant chemotherapy (16).
Park et al. evaluated prognostic factors and treatment
outcomes of patients with uterine sarcoma. The study
group consisted of 127 patients. Of these, 46 patients
had LMS of the uterus. An adjuvant chemotherapeutic
regimen containing ifosfamide was the preferred regimen
for LMS. They found that in early stage disease, adjuvant
therapy and any adjuvant treatment modality did not
significantly influence PFS or OS (17). Hsieh et al. also
found no significant survival benefit in patients with
uterine LMS who received postoperative adjuvant therapy

(18). Conversely, Durnali et al. designed a retrospective
study including 93 patients with uterine sarcoma. Of the
93 patients, 54 (58%) had LMS. The patients with LMS
were mostly stage I (48.1%). Of the 54 patients with LMS,
41 (76%) patients received adjuvant therapy. Adjuvant
therapy was chemotherapy in 20 patients, radiotherapy
in 9, and sequential chemotherapy plus radiotherapy in
12. They also performed subgroup analyses for the LMS
cohort and found that adjuvant sequential chemotherapy
plus radiotherapy showed a significantly positive effect on
OS (19).
Reed et al. published a phase III randomized study to
evaluate the role of adjuvant pelvic radiotherapy in the
treatment of stage I and II uterine sarcomas. The study group
consisted of 103 patients with LMS, 91 carcinosarcomas, and
28 endometrial stromal sarcomas. Patients were randomized
to either observation or pelvic radiation. There was no
difference in either overall or disease-free survival in patients
with LMS. Furthermore, while adjuvant pelvic radiotherapy
provided increased local control in carcinosarcoma, a
similar benefit was not observed in LMS. In fact, there was a
trend for reduced OS rates in adjuvant pelvic radiation
group, although this did not reach statistical significance
(20). In contrast to this study, Chauveinc et al. and Salazar
et al. found improved local control with adjuvant pelvic
radiotherapy without any benefit for overall survival (21,22).
Likewise, Giuntoli et al. published a retrospective review of
208 patients with uterine LMS. Of these 208 patients, 130
were at stage 1, 34 received adjuvant chemotherapy, and 36
received adjuvant radiotherapy. They found that adjuvant
pelvic radiotherapy significantly reduced the risk of pelvic
local recurrence, but adjuvant chemotherapy did not
improve clinical outcome and adjuvant treatment did not
significantly improve OS (2).
In light of these findings, we retrospectively evaluated
the outcomes of 35 patients with surgically approached,
histologically proven stage I LMS. In the current study, we
found that adjuvant therapy for surgically treated, uterusconfined disease did not improve PFS or OS. However, our
study has the inherent limitations of a retrospective study
design. In addition, the small number of patients and
many different treatment regimens in our series are other
limiting factors. Therefore, it would be wiser to wait for
the results of ongoing trials on the role of adjuvant therapy
in early stage uterine LMS before drawing definitive
conclusions.
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